Last reviewed · How we verify
Individualized dose of rituximab — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Individualized dose of rituximab (Individualized dose of rituximab) — Second Affiliated Hospital, School of Medicine, Zhejiang University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Individualized dose of rituximab TARGET | Individualized dose of rituximab | Second Affiliated Hospital, School of Medicine, Zhejiang University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Individualized dose of rituximab CI watch — RSS
- Individualized dose of rituximab CI watch — Atom
- Individualized dose of rituximab CI watch — JSON
- Individualized dose of rituximab alone — RSS
Cite this brief
Drug Landscape (2026). Individualized dose of rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/individualized-dose-of-rituximab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab